Actively Recruiting
Australian Genomics Of Chronic Allograft Dysfunction Study Observational Study of Kidney and Kidney-Pancreas Transplant Recipients
Led by Western Sydney Local Health District · Updated on 2025-07-17
500
Participants Needed
2
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are conducting the Australian Genomics of Chronic Allograft Dysfunction (AUSCAD) study, a prospective observational study at Westmead Hospital. The study enrolls patients at the time of kidney or kidney-pancreas transplant to track their post-transplant outcomes. The main goal is to understand how gene expression and immune responses relate to important outcomes such as chronic rejection and graft loss. Participants include kidney or kidney-pancreas transplant recipients who are followed over time. The study collects data on risk factors and analyzes blood, urine, and kidney tissue samples. It is non-interventional, meaning no treatments are assigned by the study, and it observes natural outcomes and gene profiles. During the study, researchers monitor participants for graft failure, allograft rejection, and gene profiles at biopsy and follow-up visits up to about 60 months. Additional outcomes tracked include death, infections, malignancies, cardiovascular events, chronic allograft dysfunction, and other transplant-related complications. Participation involves regular clinical follow-up and sample collection to better understand transplant success and challenges.
CONDITIONS
Brief Title
Australian Genomics Of Chronic Allograft Dysfunction Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Living or deceased donor kidney transplant candidate
- Any biological sex
- Aged between 18 and 75 years
- Able to understand and provide informed consent
- Deceased donor individuals with research consent obtained at organ retrieval
- Identifiable living donors who have consented to participate
You will not qualify if you...
- Prior sensitization in living donor recipients or positive crossmatch in cadaveric donor recipients
- Recipients of multiple organ transplants except kidney-pancreas transplants
- Unable or unwilling to give written informed consent or comply with study protocol
- High risk populations including pregnant women, children under 18 years, and prisoners
- Non English speaking individuals who do not understand study requirements
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - At biopsy
Participants provide blood, urine, and kidney samples for analysis and correlation with transplant outcomes.
1 visit (in-person) at time of biopsy
Duration - Up to 60 months
Participants are observed over time to monitor graft function, rejection, and other health outcomes related to their transplant.
Periodic visits depending on clinical care
Trial Site Locations
Total: 2 locations
1
Westmead Hospital
Westmead, New South Wales, Australia, 2145
Actively Recruiting
2
Westmead Institute for Medical Research
Westmead, New South Wales, Australia, 2145
Actively Recruiting
Research Team
J
Jennifer SY Li, MBBS, FRACP
P
Philip J O'Connell, MBBS, FRACP
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here